stockrowWaters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.
- Revenue
- +120.9%
- EPS
- −67.0%
- Free cash flow
- −66.7%
- Total debt
- +308.2%
Quarter to September 2026, against a year earlier
Follow WAT
Alert me
Waters Corporation (WAT) Net income
Waters Corporation's net income for fiscal 2025 was $642.6M, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $98.2M. Over the past ten years it has ranged from $20.3M (fiscal 2017) to $707.8M (fiscal 2022); the current reading is higher than 82% of that period. Waters Corporation ranks 17th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $642.6M | 0.75% |
| FY2024 | $637.8M | (0.69%) |
| FY2023 | $642.2M | (9.26%) |
| FY2022 | $707.8M | 2.15% |
| FY2021 | $692.8M | 32.84% |
| FY2020 | $521.6M | (11.93%) |
| FY2019 | $592.2M | (0.27%) |
| FY2018 | $593.8M | 2,823.51% |
| FY2017 | $20.3M | (96.11%) |
| FY2016 | $521.5M | 11.18% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $81.0M | — |
| Jun 2026 | −$136.0M | — |
| Mar 2026 | −$72.0M | — |
| Dec 2025 | $225.2M | 50.73% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. compare | $1.4B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $895.0M |
| WAT Waters Corporation | $98.2M |
| NTRA Natera, Inc. compare | −$164.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on WAT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement